TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02223312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPA-pulsed DC vaccine
Description: A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
Study: NCT04359537

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
Study: NCT02665884

Intervention type: OTHER
Intervention: Intraocular Pressure Measurement
Description: Diurnal fluctuations of intraocular pressure will be measured and compared

Intervention type: OTHER
Intervention: Intraocular Pressure Measurement
Description: Diurnal fluctuations of intraocular pressure will be measured and compared
Study: NCT01896050

Intervention type: DRUG
Intervention: anastrozole, letrozole, exemestane
Description: Patients were treated with one of the listed anti-hormonal medications for up to one year

Intervention type: DRUG
Intervention: Tamoxifen
Description: Patients were treated with tamoxifen for up to one year
Study: NCT02598960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT00531934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycline
Description: 100mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150mg po daily
Study: NCT03801460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remotely administered physiological reconditioning program
Description: Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
Study: NCT02609009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy
Description: Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Medical Care
Description: Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
Study: NCT01278862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Veneer
Description: CAD/CAM milled Lava crown with lab fabricated veneer
Study: NCT06629714

Intervention type: OTHER
Intervention: Exposure: emotional distress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.

Intervention type: OTHER
Intervention: Exposure: emotional distress status
Description: The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a sum score of PHQ-9 and GAD-7 ≥ 10 were categorized as the stressed group.
Study: NCT06714487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive stimulation through games
Description: cognitive stimulation through games
Study: NCT03680794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sampling of ophthalmic liquid
Description: aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
Study: NCT04355091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Description: It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
Study: NCT00219336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Motivational Intervention
Description: Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Only
Description: Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
Study: NCT03011372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing.
Study: NCT04817085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visant Medical Canalicular Plug
Description: Plug is inserted into the inferior canaliculi and assessed for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available canalicular plug
Description: Plug is inserted into the inferior canaliculi and assessed for 6 months
Study: NCT03137342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pepped on PrEP Package
Description: A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
Study: NCT03643354

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Epley maneuver/Barbeque maneuver
Description: Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
Study: NCT02620072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Insulin
Description: Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
Study: NCT02624778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV
Study: NCT00628979

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT
Description: cognitive- behavioral treatment for panic disorder.
Study: NCT02624778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3002813
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT01266044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture - Group 1
Description: Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture - Group 2
Description: Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard oral care recommendations. Participants in all groups will receive the same recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
Study: NCT03483337

Intervention type: OTHER
Intervention: MRI examinations
Description: Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.

Intervention type: OTHER
Intervention: MRI examinations
Description: Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
Study: NCT04452955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRL3-zumab
Description: Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)
Study: NCT04091672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Intervention (Conventional Autograft)
Description: Meshed split-thickness skin graft, with standardized wound dressings (Telfa™ Clear and Xeroform™)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Intervention (RECELL + more widely meshed autograft)
Description: More widely meshed split-thickness skin graft, Spray-on Skin™ Cells prepared using RECELL, and standardized wound dressings (Telfa™ Clear and Xeroform™)
Study: NCT04073355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Smartphone-delivered physical activity intervention
Study: NCT03404336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-Being Therapy
Description: Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
Study: NCT02683824

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI scan
Description: Undergo PET/MRI scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI scan
Description: Undergo PET/MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: radioactive tracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FP-R01-MG-F2
Description: radioactive tracer
Study: NCT02883686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alma
Description: Alma peer-mentoring
Study: NCT00866788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Administered by subcutaneous injection
Study: NCT03426514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Three-port Laparoscopic Surgery
Description: Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Laparoscopic Surgery
Description: Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
Study: NCT03804411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Automatic system guided treatment
Description: Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Automatic system guided treatment
Description: Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Addition of:~1. B -vildagliptin 100 mg/day~2. B - sitagliptin 100 mg/day,~3. B- dapagliflozin 10 mg/day~4. B- empagliflozin 10 mg/day~5. B- liraglutide 1,2-1,8 mg/day~6. B- exenatide 20 μg/day~7. B - glimepiride~8. B - gliclazide
Study: NCT02807753

Intervention type: OTHER
Intervention: Ankle and Knee Ultrasound Joint Assessment
Description: Ultrasound Examination of the ankles and knees

Intervention type: OTHER
Intervention: Ankle and Knee Ultrasound Joint Assessment
Description: Ultrasound Examination of the ankles and knees

Intervention type: OTHER
Intervention: Ankle and Knee Magnetic Resonance Imaging
Description: Ankle and Knee Magnetic Resonance Imaging
Study: NCT04397393

Intervention type: DRUG
Intervention: Midazolam
Description: Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU

Intervention type: DRUG
Intervention: Midazolam
Description: Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
Study: NCT00909766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, 30 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, 100 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 300 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 600 mg, once daily 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, oral, 1200 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, to be determined, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-830216
Description: Capsules, Oral, to be determined, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT03485846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlaprevir
Description: 100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg, tablets, taken as 100 mg per os daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg, tablets, taken as 60 mg per os daily
Study: NCT00673764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: Systane Ultra Lubricant Eye Drops 1 drop each eye one time
Study: NCT00866788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omalizumab
Description: Administered by subcutaneous injection
Study: NCT00673764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops 1 drop each eye one time
Study: NCT03129230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free nonvascularized fibula autograft
Description: Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
Study: NCT04472858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days
Study: NCT01978652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Beta-1a
Description: As specified in the treatment arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon Beta-1a
Description: As specified in the treatment arm
Study: NCT01031992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid first, than placebo
Description: For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First placebo, than Tranexamic acid.
Description: First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
Study: NCT04874896

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microbiota autotransplantation
Description: Patients received microbiota autotransplantation in capsules (1g per day) for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients will not received microbiota autotransplantation in capsules and will received usual medical care